Cerebrovascular reactivity MRI as a biomarker for cerebral small vessel disease-related cognitive decline: Multi-site validation in the MarkVCID Consortium.
Montreal Cognitive Assessment
blood oxygenation level dependent
carbon dioxide
cerebrovascular reactivity
cognitive function
magnetic resonance imaging
vascular cognitive impairment
vascular cognitive impairment and dementia
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
revised:
03
04
2024
received:
17
11
2023
accepted:
22
04
2024
medline:
2
7
2024
pubmed:
2
7
2024
entrez:
1
7
2024
Statut:
aheadofprint
Résumé
Vascular contributions to cognitive impairment and dementia (VCID) represent a major factor in cognitive decline in older adults. The present study examined the relationship between cerebrovascular reactivity (CVR) measured by magnetic resonance imaging (MRI) and cognitive function in a multi-site study, using a predefined hypothesis. We conducted the study in a total of three analysis sites and 263 subjects. Each site performed an identical CVR MRI procedure using 5% carbon dioxide inhalation. A global cognitive measure of Montreal Cognitive Assessment (MoCA) and an executive function measure of item response theory (IRT) score were used as outcomes. CVR and MoCA were positively associated, and this relationship was reproduced at all analysis sites. CVR was found to be positively associated with executive function. The predefined hypothesis on the association between CVR and a global cognitive score was validated in three independent analysis sites, providing support for CVR as a biomarker in VCID. This study measured a novel functional index of small arteries referred to as cerebrovascular reactivity (CVR). CVR was positively associated with global cognition in older adults. This finding was observed in three independent cohorts at three sites. Our statistical analysis plan was predefined before beginning data collection.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : UH3 NS100588
Pays : United States
Organisme : NIH HHS
ID : UH3 NS100606
Pays : United States
Organisme : NIH HHS
ID : UH3 NS100605
Pays : United States
Organisme : NIH HHS
ID : UH3 NS100614
Pays : United States
Organisme : NIH HHS
ID : U24 NS100591
Pays : United States
Organisme : NIH HHS
ID : R01 NS115771
Pays : United States
Organisme : NIH HHS
ID : P41 EB031771
Pays : United States
Informations de copyright
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Madigan JB, Wilcock DM, Hainsworth AH. Vascular contributions to cognitive impairment and dementia: topical review of animal models. Stroke. 2016;47:1953‐1959.
Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement. 2015;11:710‐717.
Wilcock D, Jicha G, Blacker D, et al. MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols. Alzheimers Dement. 2021;17:704‐715.
Lu H, Kashani AH, Arfanakis K, et al. MarkVCID cerebral small vessel consortium: II. Neuroimaging protocols. Alzheimers Dement. 2021;17:716‐725.
Liu P, De Vis JB, Lu H. Cerebrovascular reactivity (CVR) MRI with CO2 challenge: a technical review. Neuroimage. 2018.
Juttukonda MR, Donahue MJ. Neuroimaging of vascular reserve in patients with cerebrovascular diseases. Neuroimage. 2019;187:192‐208.
Yezhuvath US, Uh J, Cheng Y, et al. Forebrain‐dominant deficit in cerebrovascular reactivity in Alzheimer's disease. Neurobiol Aging. 2012;33:75‐82.
Silvestrini M, Pasqualetti P, Baruffaldi R, et al. Cerebrovascular reactivity and cognitive decline in patients with Alzheimer disease. Stroke. 2006;37:1010‐1015.
Cantin S, Villien M, Moreaud O, et al. Impaired cerebral vasoreactivity to CO2 in Alzheimer's disease using BOLD fMRI. Neuroimage. 2011;58:579‐587.
McKetton L, Cohn M, Tang‐Wai DF, et al. Cerebrovascular resistance in healthy aging and mild cognitive impairment. Front Aging Neurosci. 2019;11:79.
van der Thiel M, Rodriguez C, Van De Ville D, Giannakopoulos P, Haller S. Regional cerebral perfusion and cerebrovascular reactivity in elderly controls with subtle cognitive deficits. Front Aging Neurosci. 2019;11:19.
Sur S, Lin Z, Li Y, et al. Association of cerebrovascular reactivity and Alzheimer pathologic markers with cognitive performance. Neurology. 2020;95:e962‐e972.
Greenberg SM. Small vessels, big problems. N Engl J Med. 2006;354:1451‐1453.
Marstrand JR, Garde E, Rostrup E, et al. Cerebral perfusion and cerebrovascular reactivity are reduced in white matter hyperintensities. Stroke. 2002;33:972‐976.
Liu P, Jiang D, Albert M, et al. Multi‐vendor and multisite evaluation of cerebrovascular reactivity mapping using hypercapnia challenge. Neuroimage. 2021;245:118754.
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270‐279.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263‐269.
Staffaroni AM, Asken BM, Casaletto KB, et al. Development and validation of the Uniform Data Set (v3.0) executive function composite score (UDS3‐EF). Alzheimers Dement. 2021;17:574‐583.
Gottesman RF, Schneider AL, Zhou Y, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317:1443‐1450.
Lu H, Liu P, Yezhuvath U, Cheng Y, Marshall O, Ge Y. MRI mapping of cerebrovascular reactivity via gas inhalation challenges. J Vis Exp. 2014.
Burley CV, Lucas RAI, Whittaker AC, Mullinger K, Lucas SJE. The CO(2) stimulus duration and steady‐state time point used for data extraction alters the cerebrovascular reactivity outcome measure. Exp Physiol. 2020;105:893‐903.
Liu P, Baker Z, Li Y, et al. CVR‐MRICloud: an online processing tool for CO2‐inhalation and resting‐state cerebrovascular reactivity (CVR) MRI data. PLoS One. 2022;17:e0274220.
Liu P, De Vis JB, Lu H. Cerebrovascular reactivity (CVR) MRI with CO2 challenge: a technical review. Neuroimage. 2019;187:104‐115.
Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149:351‐356.
Kim D, Hughes TM, Lipford ME, et al. Relationship between cerebrovascular reactivity and cognition among people with risk of cognitive decline. Front Physiol. 2021;12:645342.
Richiardi J, Monsch AU, Haas T, et al. Altered cerebrovascular reactivity velocity in mild cognitive impairment and Alzheimer's disease. Neurobiology of aging. 2015;36:33‐41.
Thomas BP, Sheng M, Tseng BY, et al. Reduced global brain metabolism but maintained vascular function in amnestic mild cognitive impairment. J Cereb Blood Flow Metab. 2017;37:1508‐1516.
Glodzik L, Rusinek H, Brys M, et al. Framingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoreactivity to hypercapnia. J Cereb Blood Flow Metab. 2011;31:671‐679.
Sur S, Lin Z, Li Y, et al. CO(2) cerebrovascular reactivity measured with CBF‐MRI in older individuals: association with cognition, physical function, amyloid, and tau proteins. J Cereb Blood Flow Metab. 2024:271678×241240582.
Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25‐Year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol. 2017;74:1246‐1254.
Switzer AR, Cheema I, McCreary CR, et al. Cerebrovascular reactivity in cerebral amyloid angiopathy, Alzheimer disease, and mild cognitive impairment. Neurology. 2020;95:e1333‐e1340.
Case NF, Charlton A, Zwiers A, et al. Cerebral amyloid angiopathy is associated with executive dysfunction and mild cognitive impairment. Stroke. 2016;47:2010‐2016.
Lu H, Xu F, Rodrigue KM, et al. Alterations in cerebral metabolic rate and blood supply across the adult lifespan. Cerebral cortex. 2011;21:1426‐1434.
Peng SL, Chen X, Li Y, Rodrigue KM, Park DC, Lu H. Age‐related changes in cerebrovascular reactivity and their relationship to cognition: a four‐year longitudinal study. Neuroimage. 2018;174:257‐262.
Hou X, Liu P, Li Y, et al. The association between BOLD‐based cerebrovascular reactivity (CVR) and end‐tidal CO(2) in healthy subjects. Neuroimage. 2020;207:116365.
Xu F, Liu P, Pekar JJ, Lu H. Does acute caffeine ingestion alter brain metabolism in young adults? Neuroimage. 2015;110:39‐47.
Sankaralayam DS, Hu Z, Xu C, et al. Caffeine reduces cerebrovascular reactivity in addition to lowering basal perfusion. Proceedings of ISMRM 2024 Annual Meeting. Singapore, 2024.
Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134:171‐186.